European 3TR Project Unites Experts in Effort to Make Treatment More Personal and Effective

European 3TR Project Unites Experts in Effort to Make Treatment More Personal and Effective
A new public-private initiative brings academic and industry researchers from 15 European countries together in a large-scale effort to understand differences and commonalities in seven immune-mediated and inflammatory diseases, including inflammatory bowel disease (IBD), so to better predict a patient's likely response to treatment and likely disease progression. The project, called 3TR (for Taxonomy, Treatment, Targets, and Remission), will run for seven years. It gives 69 scientific and medical "partners" across a range of disciplines access to clinical data and samples, covering more than 50,000 patients who took part in 50 clinical trials, to identify disease biomarkers of importance to patient management and individualized treatment. Their goal is to bring a more scientific basis to treatment selection, rather than the "trial and error" approach of clinical trials, one expert said in a press release. Scientists will also be looking into defining molecular pathways and mechanisms across these seven diseases, and how both might be linked to therapy response and non-response in patients. In addition to IBD — which includes both ulcerative colitis and Crohn’s disease — targeted diseases are systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, and chronic obstructive pulmonary disease. With funding of €80 million (about $88.71 million) over seven years from
Subscribe or to access all post and page content.